Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ravulizumab - Alexion AstraZeneca Rare Disease

Next Previous
X
Search
Drug Profile

Ravulizumab - Alexion AstraZeneca Rare Disease

Alternative Names: ALXN 1210; ALXN 1810; ravulizumab-cwvz; Ultomiris

Latest Information Update: 26 Feb 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alexion Pharmaceuticals
  • Developer Alexion AstraZeneca Rare Disease; AstraZeneca
  • Class Anti-inflammatories; Antithrombotics; Eye disorder therapies; Monoclonal antibodies; Urologics
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Haemolytic uraemic syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemolytic uraemic syndrome; Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria
  • Registered Neuromyelitis optica
  • Phase III Acute kidney injury; IgA nephropathy; Thrombotic microangiopathies
  • Phase II Lupus nephritis
  • Discontinued Acute lung injury; Amyotrophic lateral sclerosis; COVID-19 pneumonia; Dermatomyositis; SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 17 Feb 2025 Alexion Pharmaceuticals plans the phase III AWAKE trial for Delayed graft function in Argentina, Australia, Austria, Brazil, Canada, Czech Republic, France, Germany, Italy, Poland, Portugal, South Korea, Spain, Taiwan, United Kingdom, USA (IV, Infusion), in May 2025 , (NCT06830798), (EudraCT2024-517568-48)
  • 01 Nov 2024 Alexion Pharmaceuticals completes the phase III CHAMPION-NMOSD trial in Neuromyelitis optica in USA, United Kingdom, Spain, Poland, South Korea, Japan, Italy, Germany, France, Denmark, Canada, Austria, Australia (IV) (NCT04201262)
  • 30 Aug 2024 Alexion Pharmaceuticals plans a phase III trial for Paroxysmal nocturnal haemoglobinuria (Treatment naïve) in China (IV, Infusion) (NCT06578949)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top